Relay Therapeutics RLAY
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 4th percentile, 5-year average -3.6x
Near the top of its 5-year range · 92nd percentile, 5-year average 2.3x
#4358 of 5330 stocks by PB (1 = cheapest)
Above its usual level · 61st percentile, 5-year average 468.6x
#5048 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 4.88 | – | 2.34 | 92% (pricier than usual) | #4358 of 5330 (1 = cheapest) |
| PE | -12.06 | -11.66 | -3.62 | 4% (cheaper than usual) | – |
| PS | 386.20 | 482.64 | 468.63 | 61% (pricier than usual) | #5048 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on RLAY.
Sign in to join the discussion.